GHRH in Medical Technology
AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors
and In Vivo Results for a GHRH Antagonist at the AACR Annual
Meeting in Los Angeles
QUEBEC CITY, April 13, 2007 /PRNewswire-FirstCall/ - AEterna
Zentaris Inc. , a global, pure play biopharmaceutical company
focused on endocrine therapy and oncology, today announced that it
will present two abstracts outlining first in vitro data on its
PI3K inhibitors as well as in vivo data on i...
AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist
JMR-132 at the AACR Annual Meeting in Los Angeles
JMR-132 could provide a new therapeutic approach for the treatment
of early and metastatic breast cancer
QUEBEC CITY, April 17, 2007 /PRNewswire-FirstCall/ - AEterna
Zentaris Inc. , a global, pure play biopharmaceutical company
focused on endocrine therapy and oncology, today presented an
abstract...